The United States Trade Representative (USTR) has initiated an investigation into Germany under Section 301 of the Trade Act of 1974. This investigation aims to determine if Germany's sustained low pricing of innovative medicines is an unreasonable or discriminatory practice that burdens U.S. commerce. USTR Katherine Tai stated that U.S. patients should not disproportionately bear the costs of global drug research and development, suggesting potential retaliatory tariffs on German goods. AI
RANK_REASON US government regulatory action against a foreign country. [lever_c_demoted from significant: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
